| PCT picture comparison speed test | In the study of postmenopausal women, the PCT picture comparison speed test measure after 12 months: At baseline −0.13 ± 0.13 versus 0.08 ± 0.12, at 12 months 0.32 ± 0.11 versus 0.15 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change.At baseline −0.13 ± 0.13 versus 0.08 ± 0.12, at 12 months 0.32 ± 0.11 * versus 0.15 ± 0.13; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| TMT A sequential connecting-the-dots test | In the study of postmenopausal women, the TMT A sequential connecting-the-dots test measure after 12 months: At baseline −0.02 ± 0.11 versus 0.02 ± 0.13, at 12 months 0.16 ± 0.11 versus 0.31 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline −0.02 ± 0.11 versus 0.02 ± 0.13, at 12 months 0.16 ± 0.11 versus 0.31 ± 0.11; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| Language abilities | In the study of postmenopausal women, the language abilities measure after 12 months: At baseline 0.03 ± 0.11 versus −0.03 ± 0.10, at 12 months 0.09 ± 0.11 versus 0.04 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline 0.03 ± 0.11 versus −0.03 ± 0.10, at 12 months 0.09 ± 0.11 versus 0.04 ± 0.11; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| PVT vocabulary test | In the study of postmenopausal women, the PVT vocabulary test measure after 12 months: At baseline 0.09 ± 0.12 versus −0.09 ± 0.12, at 12 months 0.20 ± 0.13 versus 0.05 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline 0.09 ± 0.12 versus −0.09 ± 0.12, at 12 months 0.20 ± 0.13 versus 0.05 ± 0.13; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| ORR oral reading recognition | In the study of postmenopausal women, the ORR oral reading recognition measure after 12 months: At baseline −0.02 ± 0.12 versus 0.02 ± 0.12, at 12 months −0.02 ± 0.11 versus 0.04 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline −0.02 ± 0.12 versus 0.02 ± 0.12, at 12 months −0.02 ± 0.11 versus 0.04 ± 0.10; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| Episodic memory | In the study of postmenopausal women, the episodic memory measure after 12 months: At baseline −0.47 ± 0.10 versus −0.49 ± 0.09, at 12 months −0.19 ± 0.11 versus −0.27 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline −0.47 ± 0.10 versus −0.49 ± 0.09, at 12 months −0.19 ± 0.11 versus −0.27 ± 0.10; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| PSM picture sequence memory test | In the study of postmenopausal women, the PSM picture sequence memory test measure after 12 months: At baseline −0.47 ± 0.10 versus −0.49 ± 0.09, at 12 months −0.19 ± 0.11 versus −0.27 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline −0.47 ± 0.10 versus −0.49 ± 0.09, at 12 months −0.19 ± 0.11 versus −0.27 ± 0.10; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| Verbal memory | In the study of postmenopausal women, the verbal memory measure after 12 months: At baseline −0.001 ± 0.1 versus 0.001 ± 0.1, at 12 months 0.12 ± 0.10 versus 0.17 ± 0.12; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline −0.001 ± 0.1 versus 0.001 ± 0.1, at 12 months 0.12 ± 0.10 versus 0.17 ± 0.12; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| RAVLT immediate word recall | In the study of postmenopausal women, the RAVLT immediate word recall measure after 12 months: At baseline −0.02 ± 0.07 versus 0.02 ± 0.07, at 12 months 0.07 ± 0.06 versus 0.07 ± 0.06; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline −0.02 ± 0.07 versus 0.02 ± 0.07, at 12 months 0.07 ± 0.06 versus 0.07 ± 0.06; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| RAVLT delayed word recall | In the study of postmenopausal women, the RAVLT delayed word recall measure after 12 months: At baseline 0.02 ± 0.15 versus −0.02 ± 0.15, at 12 months 0.17 ± 0.16 versus 0.28 ± 0.19; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline 0.02 ± 0.15 versus −0.02 ± 0.15, at 12 months 0.17 ± 0.16 versus 0.28 ± 0.19; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| Working memory | In the study of postmenopausal women, the working memory measure after 12 months: At baseline −0.04 ± 0.10 versus 0.04 ± 0.10, at 12 months 0.05 ± 0.09 versus 0.06 ± 0.09; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline −0.04 ± 0.10 versus 0.04 ± 0.10, at 12 months 0.05 ± 0.09 versus 0.06 ± 0.09; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| LSWM working memory test | In the study of postmenopausal women, the LSWM working memory test measure after 12 months: At baseline −0.11 ± 0.12 versus 0.11 ± 0.11, at 12 months −0.03 ± 0.13 versus 0.08 ± 0.14; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline −0.11 ± 0.12 versus 0.11 ± 0.11, at 12 months −0.03 ± 0.13 versus 0.08 ± 0.14; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| FSS spatial memory test | In the study of postmenopausal women, the FSS spatial memory test measure after 12 months: At baseline 0.04 ± 0.11 versus −0.04 ± 0.12, at 12 months 0.12 ± 0.10 versus 0.06 ± 0.12; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline 0.04 ± 0.11 versus −0.04 ± 0.12, at 12 months 0.12 ± 0.10 versus 0.06 ± 0.12; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| Flexibility in switching between mental tasks | In the study of postmenopausal women, the cognitive flexibility measure after 12 months: At baseline 0.03 ± 0.08 versus −0.03 ± 0.12, at 12 months 0.82 ± 0.07 versus 0.78 ± 0.08; z-scores, mean ± SEM; values as in the table. The authors reported a statistically significant between-group difference in change.At baseline 0.03 ± 0.08 versus −0.03 ± 0.12, at 12 months 0.82 ± 0.07 * versus 0.78 ± 0.08; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| DCCS rule-switching test | In the study of postmenopausal women, the DCCS rule-switching test measure after 12 months: At baseline 0.05 ± 0.09 versus −0.05 ± 0.14, at 12 months 0.23 ± 0.10 versus 0.10 ± 0.13; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline 0.05 ± 0.09 versus −0.05 ± 0.14, at 12 months 0.23 ± 0.10 versus 0.10 ± 0.13; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| FICA attention and inhibition test | In the study of postmenopausal women, the FICA attention and inhibition test measure after 12 months: At baseline 0.08 ± 0.11 versus −0.08 ± 0.12, at 12 months 0.26 ± 0.12 versus 0.22 ± 0.11; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline 0.08 ± 0.11 versus −0.08 ± 0.12, at 12 months 0.26 ± 0.12 versus 0.22 ± 0.11; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| Sequential connecting of dots in the TMT | In the study of postmenopausal women, the TMT test score measure after 12 months: At baseline −0.02 ± 0.19 versus 0.02 ± 0.21, at 12 months 1.97 ± 0.11 versus 2.01 ± 0.10; z-scores, mean ± SEM; values as in the table. The authors did not report a statistically significant between-group difference in change.At baseline −0.02 ± 0.19 versus 0.02 ± 0.21, at 12 months 1.97 ± 0.11 versus 2.01 ± 0.10; z-scores, mean ± SEM; values as in the table. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The study compared many cognitive measures, and completeness of observations for each individual row was not specified. | 11 trialSustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗ | Postmenopausal women; the table shows 63 in the resveratrol group and 66 in the placebo group at month 12 | - Sustained Cerebrovascular and Cognitive Benefits of Resveratrol in Postmenopausal Women ↗
|
|---|
| Change in VO₂max | In 27 older men following the same training program, the increase in VO₂max was smaller with 250 mg of trans-resveratrol daily for 8 weeks than with placebo: VO₂max increase: 308±46 mL/min with resveratrol versus 444±38 mL/min with placebo (mean ± SEM), p<0.05; the increase in the placebo group was 45% greater.VO₂max increase: 308±46 mL/min with resveratrol versus 444±38 mL/min with placebo (mean ± SEM), p<0.05; the increase in the placebo group was 45% greater. | 2/4 LowOne small study with a specific training program in older men limits generalizability. The between-group result concerns change in VO₂max, not all measures of fitness. | 11 trialResveratrol blunts the positive effects of exercise training on cardiovascular health in aged men ↗ | 27 older men, 14/13 | - Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men ↗
|
|---|
| Soreness after a marathon | According to a systematic review, in the Laupheimer 2014 study: the review reports no significant between-group difference in soreness after a marathon.The review reports no significant between-group difference in soreness after a marathon. | 1/4 Very lowOne small study and its specific participants and exercise loads limit generalizability. The review reports direction and significance, but gives no numerical between-group effect for this outcome. | 11 trial in the reviewEffects of Resveratrol Supplementation on Delayed Onset Muscle Soreness and Muscle Recovery: A Systematic Review ↗ | 7 male athletes, 3/4 | - Effects of Resveratrol Supplementation on Delayed Onset Muscle Soreness and Muscle Recovery: A Systematic Review ↗
|
|---|
| Muscle pain and recovery after jumping | The review reports that in Huang 2021 muscle pain and recovery of performance after jumping exercise were better in the resveratrol group; numerical between-group estimates were not provided.The review reports better pain and recovery measures after exercise; quantitative between-group estimates are not provided in the review table. | 1/4 Very lowOne small study and its specific participants and exercise loads limit generalizability. The review reports direction and significance, but gives no numerical between-group effect for this outcome. | 11 trial in the reviewEffects of Resveratrol Supplementation on Delayed Onset Muscle Soreness and Muscle Recovery: A Systematic Review ↗ | 36 men without athletic training, 12 per group | - Effects of Resveratrol Supplementation on Delayed Onset Muscle Soreness and Muscle Recovery: A Systematic Review ↗
|
|---|
| High-intensity cycling test performance | According to a systematic review, in the Tsao 2021 study: the review reports no significant improvement in high-intensity cycling performance.The review reports no significant improvement in high-intensity cycling performance. | 1/4 Very lowOne small study and its specific participants and exercise loads limit generalizability. The review reports direction and significance, but gives no numerical between-group effect for this outcome. | 11 trial in the reviewEffects of Resveratrol Supplementation on Delayed Onset Muscle Soreness and Muscle Recovery: A Systematic Review ↗ | 8 physically active men, crossover comparison | - Effects of Resveratrol Supplementation on Delayed Onset Muscle Soreness and Muscle Recovery: A Systematic Review ↗
|
|---|
| Pain and strength loss after eccentric exercise | According to a systematic review, in the Kristoffersen 2022 study: the review reports reduced pain at 24 hours but no prevention of strength loss.The review reports reduced pain at 24 hours but no prevention of strength loss. | 1/4 Very lowOne small study and its specific participants and exercise loads limit generalizability. The review reports direction and significance, but gives no numerical between-group effect for this outcome. | 11 trial in the reviewEffects of Resveratrol Supplementation on Delayed Onset Muscle Soreness and Muscle Recovery: A Systematic Review ↗ | 18 untrained adults, 9/9 | - Effects of Resveratrol Supplementation on Delayed Onset Muscle Soreness and Muscle Recovery: A Systematic Review ↗
|
|---|
| Overall mental task performance: crossover comparison | In the RESHAW crossover study of postmenopausal women, for the overall cognitive score: Cohen d=0.170, p=0.005; the authors reported a 33% relative change in the composite score.Cohen d=0.170, p=0.005; the authors reported a 33% relative change in the composite score. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The number analyzed for this outcome is not separately disclosed in the available abstract; full text is available by subscription. | 11 trialLong-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study ↗ | 125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established | - Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study ↗
|
|---|
| Composite pain score | In the RESHAW crossover study of postmenopausal women, for the composite pain score: the authors reported improvement in the composite pain score, p<0.001; a quantitative between-group difference was not provided in the available abstract.The authors reported improvement in the composite pain score, p<0.001; a quantitative between-group difference was not provided in the available abstract. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The number analyzed for this outcome is not separately disclosed in the available abstract; full text is available by subscription. | 11 trialLong-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial ↗ | 125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established | - Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial ↗
|
|---|
| Somatic symptoms | In the RESHAW crossover study of postmenopausal women, for somatic symptoms: the authors reported improvement in somatic symptoms, p=0.024; a quantitative difference was not provided in the abstract.The authors reported improvement in somatic symptoms, p=0.024; a quantitative difference was not provided in the abstract. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The number analyzed for this outcome is not separately disclosed in the available abstract; full text is available by subscription. | 11 trialLong-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial ↗ | 125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established | - Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial ↗
|
|---|
| Overall well-being | In the RESHAW crossover study of postmenopausal women, for overall well-being: the authors reported improvement in overall well-being, p=0.010; a quantitative difference was not provided in the abstract.The authors reported improvement in overall well-being, p=0.010; a quantitative difference was not provided in the abstract. | 1/4 Very lowOne cohort of postmenopausal women limits generalizability to other groups. The number analyzed for this outcome is not separately disclosed in the available abstract; full text is available by subscription. | 11 trialLong-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial ↗ | 125 postmenopausal women in the RESHAW crossover study; the number analyzed for the individual outcome is not established | - Long-term resveratrol supplementation improves pain perception, menopausal symptoms, and overall well-being in postmenopausal women: findings from a 24-month randomized, controlled, crossover trial ↗
|
|---|
| Information processing speed (PCT) | A review of postmenopausal women found no statistically significant difference in PCT: WMD +0.088 (95% CI −0.099…+0.274), p=0.358 The pooled RESHAW publications belong to one program.WMD +0.088 (95% CI −0.099…+0.274), p=0.358 | 1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect. | 11 review of studiesEffects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗ | Postmenopausal women in the studies in the review | - Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗
|
|---|
| TMT A task performance | A review of postmenopausal women found no statistically significant difference in TMT A: WMD +0.026 (95% CI −0.147…+0.199), p=0.769 The pooled RESHAW publications belong to one program.WMD +0.026 (95% CI −0.147…+0.199), p=0.769 | 1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect. | 11 review of studiesEffects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗ | Postmenopausal women in the studies in the review | - Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗
|
|---|
| Immediate word recall (RAVLT) | A review of postmenopausal women found no statistically significant difference in RAVLT immediate recall: WMD +0.004 (95% CI −0.102…+0.110), p=0.939 The pooled RESHAW publications belong to one program.WMD +0.004 (95% CI −0.102…+0.110), p=0.939 | 1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect. | 11 review of studiesEffects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗ | Postmenopausal women in the studies in the review | - Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗
|
|---|
| Delayed word recall (RAVLT) | A review of postmenopausal women found no statistically significant difference in RAVLT delayed recall: WMD +0.064 (95% CI −0.550…+0.678), p=0.838 The pooled RESHAW publications belong to one program.WMD +0.064 (95% CI −0.550…+0.678), p=0.838 | 1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect. | 11 review of studiesEffects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗ | Postmenopausal women in the studies in the review | - Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗
|
|---|
| Working memory (LSWM) | A review of postmenopausal women found no statistically significant difference in LSWM working memory: WMD −0.066 (95% CI −0.293…+0.161), p=0.567 The pooled RESHAW publications belong to one program.WMD −0.066 (95% CI −0.293…+0.161), p=0.567 | 1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect. | 11 review of studiesEffects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗ | Postmenopausal women in the studies in the review | - Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗
|
|---|
| Spatial memory (FSS) | A review of postmenopausal women found no statistically significant difference in FSS working memory: WMD +0.180 (95% CI −0.021…+0.380), p=0.079 The pooled RESHAW publications belong to one program.WMD +0.180 (95% CI −0.021…+0.380), p=0.079 | 1/4 Very lowThe review combines interim and crossover publications from the same RESHAW program, so the rows are not independent participants or trials. The number of unique people and the number of participants in the analysis of this outcome are not established, and the confidence interval includes no effect. | 11 review of studiesEffects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗ | Postmenopausal women in the studies in the review | - Effects of resveratrol on postmenopausal women: a systematic review and meta-analysis ↗
|
|---|
| Body weight | A review of adults with various conditions, including cardiometabolic disorders, reported for body weight: SMD +0.041 (95% CI −0.136…+0.217). Study conditions and source limitations are considered separately.SMD +0.041 (95% CI −0.136…+0.217). | 2/4 LowFor body weight, the confidence interval includes no difference; the exact number of unique participants in this analysis is not established. The review combined different groups and doses; selection of individual study arms and independence of some publications are not entirely clear. | 11 review; 19 estimate rows for this outcome; number of unique participants not establishedResveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗ | Heterogeneous groups of adults; included conditions and groups: type 2 diabetes; non-alcoholic fatty liver disease; metabolic syndrome; obesity; in some studies, no other diseases; healthy older adults. | - Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗
|
|---|
| Fat mass | A review of adults with various conditions, including cardiometabolic disorders, reported for fat mass: SMD −0.202 (95% CI −0.410…+0.007). Study conditions and source limitations are considered separately.SMD −0.202 (95% CI −0.410…+0.007). | 2/4 LowFor fat mass, the confidence interval includes no difference; the exact number of unique participants in this analysis is not established. The review combined different groups and doses; selection of individual study arms and independence of some publications are not entirely clear. | 11 review; 6 estimate rows for this outcome; number of unique participants not establishedResveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗ | Heterogeneous groups of adults; included conditions and groups: metabolic syndrome; obesity; in some studies, no other diseases; type 2 diabetes; healthy older adults. | - Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗
|
|---|
| BMI | A review of adults with various conditions, including cardiometabolic disorders, reported for BMI: SMD −0.075 (95% CI −0.193…+0.043). Study conditions and source limitations are considered separately.SMD −0.075 (95% CI −0.193…+0.043). | 3/4 ModerateFor BMI, the confidence interval includes no difference; the exact number of unique participants in this analysis is not established. For some rows in the review, it is unclear which arms were selected and whether individual publications refer to the same participants. | 11 review; 21 estimate rows for this outcome; number of unique participants not establishedResveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗ | Heterogeneous groups of adults; included conditions and groups: type 2 diabetes; non-alcoholic fatty liver disease; metabolic syndrome; overweight or moderate obesity; obesity; in some studies, no other diseases; healthy older adults; dyslipidemia; ulcerative colitis. | - Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗
|
|---|
| Hip circumference | A review of adults with various conditions, including cardiometabolic disorders, reported for hip circumference: SMD −0.037 (95% CI −0.270…+0.197). Study conditions and source limitations are considered separately.SMD −0.037 (95% CI −0.270…+0.197). | 3/4 ModerateFor hip circumference, the confidence interval includes no difference; the exact number of unique participants in this analysis is not established. The review does not make clear which arms were included in individual estimates; both groups compared in one study followed a Mediterranean diet. | 11 review; 6 estimate rows for this outcome; number of unique participants not establishedResveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗ | Heterogeneous groups of adults; included conditions and groups: non-alcoholic fatty liver disease; type 2 diabetes; ulcerative colitis. | - Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗
|
|---|
| Waist circumference | A review of adults with various conditions, including cardiometabolic disorders, reported for waist circumference: SMD −0.081 (95% CI −0.224…+0.062). Study conditions and source limitations are considered separately.SMD −0.081 (95% CI −0.224…+0.062). | 3/4 ModerateFor waist circumference, the confidence interval includes no difference; the exact number of unique participants in this analysis is not established. For some rows in the review, it is unclear which arms were selected and whether individual publications refer to the same participants. | 11 review; 14 estimate rows for this outcome; number of unique participants not establishedResveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗ | Heterogeneous groups of adults; included conditions and groups: non-alcoholic fatty liver disease; metabolic syndrome; obesity; in some studies, no other diseases; type 2 diabetes; dyslipidemia; ulcerative colitis. | - Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases ↗
|
|---|